Assignee
LENTIGEN TECH INC
US·35 granted patents·20 pending applications·149 citations·filing 2016–2025
Top patents by PatentIndex Score
55 records- 0197US10844128B2Compositions and methods for treating cancer with anti-CD123 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Nov 24, 2020·20 cites·11 claims
- 0297US10442867B2Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 15, 2019·17 cites·7 claims
- 0397US10428141B2Compositions and methods for treating cancer with anti-ROR1 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 1, 2019·15 cites·13 claims
- 0496US11242389B2Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Feb 8, 2022·5 cites·20 claims
- 0596US10183993B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Jan 22, 2019·11 cites·27 claims
- 0695US11208455B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2019·Granted Dec 28, 2021·6 cites·8 claims
- 0795US10689431B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2018·Granted Jun 23, 2020·8 cites·9 claims
- 0895US10501539B2Compositions and methods for treating cancer with anti-CD19 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Dec 10, 2019·8 cites·6 claims
- 0995US10426797B2Compositions and methods for treating cancer with anti-CD33 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 1, 2019·19 cites·10 claims
- 1093US11103533B2Compositions and methods for treating cancer with anti-CD38 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Aug 31, 2021·7 cites·13 claims
- 1193US10639329B2Method to treat cancer with engineered T-cellsLENTIGEN TECH INC·Filed 2016·Granted May 5, 2020·12 cites·6 claims
- 1293US10550179B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Feb 4, 2020·6 cites·18 claims
- 1392US11052112B2Compositions and methods for treating cancer with anti-BCMA immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Jul 6, 2021·5 cites·9 claims
- 1489US11453712B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2017·Granted Sep 27, 2022·2 cites·8 claims
- 1588US11590169B1Compositions and methods for treating cancer with anti-CD123 immunotherapyLENTIGEN TECH INC·Filed 2022·Granted Feb 28, 2023·2 cites·20 claims
- 1687US11453719B2Compositions and methods for treating cancer with anti-ROR1 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Sep 27, 2022·2 cites·19 claims
- 1787US2024043497A1Compositions and Methods for Treating Cancer with DuoCARsLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 1887US2025367291A1Compositions and Methods for Treating Cancer with DuoCARsLENTIGEN TECH INC·Filed 2025·Application pending·0 cites
- 1986US11802142B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2020·Granted Oct 31, 2023·1 cites·7 claims
- 2086US2024025962A1Compositions and methods for treating cancer with duocarsLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 2184US10894819B2Compositions and methods for treating HIV/AIDS with immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Jan 19, 2021·2 cites·18 claims
- 2282US2022281946A1Compositions and Methods for Treating Cancer with DuoCARsLENTIGEN TECH INC·Filed 2022·Application pending·0 cites
- 2381US12365718B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2021·Granted Jul 22, 2025·0 cites·8 claims
- 2481US11464801B2Compositions and methods for treating cancer with anti-CD33 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Oct 11, 2022·1 cites·15 claims
- 2580US12540179B2Compositions and methods for treating cancer with anti-ROR1 immunotherapyLENTIGEN TECH INC·Filed 2022·Granted Feb 3, 2026·0 cites·13 claims
- 2680US2025084166A1Compositions and Methods for Treating Cancer with Anti-CD19/CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 2780US2024067724A1Compositions and Methods for Treating Cancer with Anti-CD19 ImmunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 2879US2024108706A1Compositions and Methods for Treating Cancer with Anti-CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 2979US2024150773A1Chimeric Antigen Receptors and Methods of UseLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 3079US2025090631A1Method to Treat Cancer with Engineered T-CellsLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 3178US2024309102A1Compositions and Methods for Treating Cancer with Anti-CD123 ImmunotherapyLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 3278US2024368256A1Compositions and methods for treating hiv/aids with immunotherapyLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 3377US2024034802A1Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 3477US2026070978A1Compositions and Methods for Treating Cancer with Anti-CD19/CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2025·Application pending·0 cites
- 3576US12371490B2Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapyLENTIGEN TECH INC·Filed 2022·Granted Jul 29, 2025·0 cites·27 claims
- 3676US11905515B2Chimeric antigen receptors and methods of useLENTIGEN TECH INC·Filed 2019·Granted Feb 20, 2024·0 cites·2 claims
- 3776US2026015403A1Compositions and methods for treating cancer with anti-bcma immunotherapyLENTIGEN TECH INC·Filed 2025·Application pending·0 cites
- 3875US11708408B2Compositions and methods for treating cancer with anti-CD19 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Jul 25, 2023·0 cites·17 claims
- 3974US2023241103A1Compositions and Methods for Treating Cancer with Anti-CD33 ImmunotherapyLENTIGEN TECH INC·Filed 2022·Application pending·0 cites
- 4072US12037403B2Compositions and methods for treating cancer with anti-CD123 immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Jul 16, 2024·0 cites·8 claims
- 4172US11680103B2Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Jun 20, 2023·0 cites·6 claims
- 4271US12391958B2Compositions and methods for treating cancer with anti-CD38 immunotherapyLENTIGEN TECH INC·Filed 2021·Granted Aug 19, 2025·0 cites·21 claims
- 4371US12391740B2Compositions and methods for treating cancer with anti-BCMA immunotherapyLENTIGEN TECH INC·Filed 2021·Granted Aug 19, 2025·0 cites·23 claims
- 4470US12122831B2Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Oct 22, 2024·0 cites·16 claims
- 4570US12024554B2Compositions and methods for treating HIV/AIDS with immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Jul 2, 2024·0 cites·15 claims
- 4670US11497770B2Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapyLENTIGEN TECH INC·Filed 2021·Granted Nov 15, 2022·0 cites·5 claims
- 4770US2023256020A1Compositions and Methods for Treating Cancer with TSLPR-CD19 or TSLPR-CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2022·Application pending·0 cites
- 4870US2024307448A1Compositions and methods for treating cancer with self-driving chimeric antigen receptorsLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 4968US11970528B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Apr 30, 2024·0 cites·18 claims
- 5066US12193995B2Method to treat cancer with engineered T-cellsLENTIGEN TECH INC·Filed 2020·Granted Jan 14, 2025·0 cites·12 claims
Showing the top 50 of 55 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →